Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
TG THERAPEUTICS, INC. (TGTX)
|
Add to portfolio |
|
|
|
| Price: |
$20.45
| | Metrics |
| OS: |
151.0
|
M
| |
-434
|
% ROE
|
| Market cap: |
$3.09
|
B
| |
|
|
|
Net cash:
|
$47.2
|
M
| |
$0.31
|
per share
|
|
EV:
|
$3.04
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($168)
|
M
| |
|
|
|
EBIT
|
($169)
|
M
| |
|
|
| EPS |
($1.27)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 2.8 | 6.7 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
| Revenue growth | -58.4% | 4300.7% | 0.0% | 0.0% | 0.0% | 0.0% | -0.3% | 0.0% |
| Cost of goods sold | 0.3 | 0.8 | -315.3 | -178.7 | -182.4 | -124.9 | -84.2 | -67.5 |
| Gross profit | 2.5 | 5.9 | 315.4 | 178.9 | 182.6 | 125.0 | 84.4 | 67.7 |
| Gross margin | 90.5% | 88.2% | 207513.8% | 117673.0% | 120116.4% | 82269.1% | 55523.0% | 44411.2% |
| Selling, general and administrative | 134.1 | 219.0 | 149.4 | 24.5 | | | | |
| Research and development | 125.4 | 222.6 | 165.9 | 154.2 | 159.4 | 102.5 | 69.2 | 47.7 |
| General and administrative | | | | | 23.0 | 22.4 | 15.0 | 19.8 |
| EBITA | -192.6 | -344.6 | -273.4 | -168.9 | -174.4 | -118.7 | -79.0 | -63.2 |
| EBITA margin | -6916.6% | -5151.1% | -179853.9% | -111100.7% | -114736.8% | -78100.0% | -51953.3% | -41461.9% |
| Amortization of intangibles | 0.2 | 0.2 | 0.2 | 0.2 | | | | |
| EBIT | -192.8 | -344.8 | -273.6 | -169.1 | -174.4 | -118.7 | -79.0 | -63.2 |
| EBIT margin | -6924.2% | -5154.3% | -179996.1% | -111220.4% | -114736.8% | -78100.0% | -51953.3% | -41461.9% |
| Pre-tax income | -198.3 | -348.1 | -0.3 | -0.2 | -0.2 | -0.1 | -78.3 | -62.9 |
| Income taxes | -41.7 | -73.1 | -0.1 | 0.0 | 0.0 | 0.0 | -26.6 | 0.0 |
| Tax rate | 21.0% | 21.0% | 21.0% | 21.0% | 21.0% | 34.0% | 34.0% | 0.0% |
| Net income | -198.3 | -348.1 | -279.4 | -172.9 | -173.5 | -118.5 | -78.3 | -62.9 |
| Net margin | -7121.5% | -5204.1% | -183803.3% | -113730.9% | -114132.9% | -77944.7% | -51482.2% | -41310.0% |
| |
| Diluted EPS | ($1.46) | ($2.63) | ($2.42) | ($1.96) | ($2.30) | ($1.91) | ($1.60) | ($1.38) |
| Shares outstanding (diluted) | 135.4 | 132.2 | 115.3 | 88.4 | 75.5 | 62.1 | 49.0 | 45.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|